Understanding FET100% (S): Normal vs Optimal Ranges

?What is FET100% (S)?

FET100% (S) measures the fetal fraction—the percentage of cell-free fetal DNA (cfDNA) present in maternal serum. This marker is used in non-invasive prenatal testing (NIPT) to assess the quality and reliability of prenatal genetic screening results. A sufficient fetal fraction (typically ≥4%) indicates adequate fetal DNA for accurate chromosomal analysis.

!Why It Matters

Fetal fraction is a critical quality metric for prenatal screening accuracy. Low or absent fetal fraction may suggest inadequate fetal DNA in the sample and can be associated with test failure, maternal obesity, or early gestational age—conditions that could indicate the need for repeat testing or alternative screening approaches. Higher fetal fractions generally correlate with more reliable results for detecting chromosomal abnormalities.

Reference Ranges

Lab normal ranges may vary between laboratories. Optimal and longevity targets are based on research literature and should be interpreted with your physician.

Symptoms of Imbalance

• No direct symptoms; this is a technical quality marker
• Low fetal fraction may prompt repeat testing or alternative prenatal screening
• Inability to obtain clear prenatal genetic screening results
• Concern about test validity in early pregnancy or maternal factors

How to Improve Your Levels

• 1Ensure accurate gestational age assessment before testing (fetal fraction increases with gestational age)
• 2Maintain adequate hydration and follow pre-test instructions provided by the laboratory
• 3Discuss maternal factors (obesity, anticoagulation use) with your healthcare provider before testing
• 4Repeat testing at a later gestational age if initial fetal fraction is borderline or low
• 5Confirm sample collection and handling procedures were performed correctly
• 6Consider alternative prenatal screening methods if repeated tests show consistently low fetal fraction

When to Test

FET100% (S) is assessed as part of non-invasive prenatal testing (NIPT), typically performed between 9 and 22 weeks of gestation. Testing is commonly offered to all pregnant individuals or recommended for those with increased risk factors for chromosomal abnormalities.

Related Biomarkers